Revenue and Income - For the year ended December 31, 2024, revenue totaled $1.0 million, an increase from $0 in 2023, attributed to an upfront license fee from Kuva Labs, Inc.[375] - Total other income decreased by approximately $0.9 million or 35.9% to $1.6 million in 2024, primarily due to reduced investment income[377] Expenses and Loss - Total operating expenses decreased by $2.3 million or 8.9% to $23.4 million in 2024 from $25.7 million in 2023, driven by reductions in research and development and general administrative expenses[376] - Net loss for the year ended December 31, 2024, was $19.985 million, a slight improvement from a net loss of $20.840 million in 2023, reflecting a decrease of $855,000[374] Cash Flow and Liquidity - Cash used in operating activities was approximately $19.4 million for 2024, compared to $20.0 million in 2023, indicating a reduction in cash burn[383] - Cash provided by investing activities increased to approximately $13.2 million in 2024 from $10.1 million in 2023, primarily due to net sales of marketable securities[385] - As of December 31, 2024, the company had cash, cash equivalents, and marketable securities of approximately $31.2 million, with working capital of approximately $29.0 million[380] - The company expects to meet its short and long-term liquidity needs through existing cash balances and potential issuances of debt or equity securities[389] Clinical Studies - The company is currently conducting several Phase 2 clinical studies globally for its investigational product, certepetide, targeting various solid tumors[372] Stock Issuance - The company issued 3,779 shares of common stock under the ATM Agreement for net proceeds of $10,074 during the twelve months ended December 31, 2024[391]
Lisata Therapeutics(LSTA) - 2024 Q4 - Annual Report